Matthew Hoskin Chief Executive Officer 

Matthew joined Sienna early in 2014 and brought a wealth of experience in leading and growing medtech companies in both the local and international markets. His keen interest in cancer diagnostics has seen him work with a number of multi-national companies specialising in antibodies and reagent detection systems, automated IHC / ICC stainers, tissue processors, pathology capital equipment as well as consumables and oncology pharmaceuticals.

With over 20 years’ experience leading business in the medtech and healthcare sectors, including Siemens Medical, Leica Biosystems and Hospira, Matthew played a key role in driving the growth at Vision Biosystems which became one of Australia’s most profitable biotechs and ultimately sold for ~AUD$800 million.

At Sienna, Matthew’s efforts are focused on company growth and achieving profitability through the delivery of high-quality products that address unmet market needs, and delivering them with commercial excellence. His extensive experience in driving revenue and profit whilst ensuring operational excellence in all aspects of the business is invaluable to Sienna in its pursuit of global diagnostics success.

Tony Di Pietro Chief Financial Officer & Company Secretary 

Tony commenced in the role of Chief Financial Officer in November 2014 and was appointed Company Secretary in February 2015. He is a chartered accountant with significant corporate accounting experience, gained both in Australia and the UK. He also holds a Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia. Tony’s experience spans many industries including biotechnology, resources, banking, patient transport, security and parking, having been employed by companies such as BHP Ltd (now BHP Billiton Ltd), ExxonMobil Ltd, HSBC Ltd and Wilson Group. Prior to his appointment at Sienna, Tony was employed at Acrux Limited, where he was a key member of management for more than 10 years. During this period, Acrux transitioned from a small loss-making public company to an ASX listed company generating significant profits.

Dr Peter French Strategic Technology Advisor 

Peter has over 40 years’ experience in cell and molecular biology and has published across a wide range of areas, including oncology, immunology, microbiology and neuroscience.

Dr French was a Director of several biotech companies in Australia and the US, including Cryosite, Probiomics Ltd., Benetic Biopharma, and most recently served as CEO of Sevident.

Peter is focussed on sourcing, evaluating and ultimately acquiring new technologies that can become products in Sienna’s development and commercialisation pipeline. Peter’s work ensures that Sienna has both a near-term and a long-term strategy for technology evolution and growth.

Dr Wayne Jensen Research & Development Director 

Wayne has over 25 years’ experience in the IVD medical device industry, with a track record in developing IVD products from inception to completion, enabling in-house production and international market release.

He also has deep experience in partnered product development as a conduit to market release with international IVD companies, including Abbott, Roche, Siemens, Beckman Coulter and Sigma. He previously held roles in research and development with companies including Universal Biosensors and Thermo Fisher Scientific.

As the head of R&D across the Sienna portfolio, Wayne manages the R&D strategic planning and implementation, including the integration of new technologies acquired or in-licensed by Sienna. He and his team are currently developing and executing plans to manufacture the SIENNET ™ product line.

Sign up for updates